Temperature-responsive drug-polymer conjugates and their application to drug delivery

The temperature-responsive drug-polymer conjugate forms micellar aggregates in the lungs, addressing inefficient lung delivery of chemically modified antisense oligonucleotides by enhancing lung accumulation and reducing systemic distribution.

JP7578988B2Active Publication Date: 2024-11-07THE UNIV OF TOKYO
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2021535327
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-26
Filing Date
2020-07-27
Publication Date
2024-11-07
Estimated Expiration
2040-07-27

AI Technical Summary

Technical Problem

Existing drug delivery methods, such as intratracheal administration of chemically modified antisense oligonucleotides, result in accumulation in non-target organs like the liver and kidneys, leading to inefficient gene knockdown in the lungs.

Method used

A temperature-responsive drug-polymer conjugate is developed, comprising a temperature-responsive polymer segment and a drug attached to its end, forming micellar aggregates at temperatures above the lower critical solution temperature (LCST), which can be administered nasally or intratracheally to efficiently deliver drugs to the lungs.

Benefits of technology

The micellar aggregates are absorbed through the lungs, reducing systemic distribution and enhancing drug accumulation in lung tissue, thereby achieving efficient drug delivery and gene knockdown with reduced cytotoxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007578988000008
    Figure 0007578988000008
  • Figure 0007578988000009
    Figure 0007578988000009
  • Figure 0007578988000010
    Figure 0007578988000010
Patent Text Reader

Abstract

The present invention has been made to solve the problem and the main purpose thereof is to provide a method for efficiently delivering a drug to the lungs. In the present invention, by using a temperature-responsive drug / polymer compound, aggregates of the compound can be formed in an aqueous medium in a temperature-dependent manner. The aggregates can be absorbed transpulmonarily and can be suitably retained in lung tissues, thereby achieving efficient delivery of the drug to the lungs.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a temperature-responsive drug-polymer conjugate and the application of the conjugate in drug delivery. More specifically, the present invention relates to a temperature-responsive drug-polymer conjugate, a micellar aggregate containing the drug-polymer conjugate, and a method for using or preparing the same. [Background technology]

[0002] Chemically modified antisense oligonucleotides (ASOs) containing phosphorothioate bonds and bridged nucleic acids (LNA or BNA) are one of the promising therapeutic candidates for various intractable diseases such as cancer because they have high resistance to enzymatic degradation and high affinity for target RNA that enables gene knockdown.

[0003] Intratracheal administration also holds promise as a method for delivering and concentrating drugs in the lungs without distribution to other tissues or organs.

[0004] However, it has been reported that when a single chemically modified antisense oligonucleotide (naked ASO) is inhaled into a mouse via the trachea, it accumulates in the liver and kidneys, and does not show significant gene knockdown in the lungs (Non-Patent Document 1). [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Molecular Therapy,vol.19,No.12,2163-2168,Dec.2011 Summary of the Invention [Problem to be solved by the invention]

[0006] The present invention has been made to solve the above problems, and a main object of the present invention is to provide a method for efficiently delivering a drug to the lungs. [Means for solving the problem]

[0007] According to one aspect of the present invention, there is provided a temperature-responsive drug-polymer conjugate, the drug-polymer conjugate comprising a temperature-responsive polymer segment and a drug bound to an end of the temperature-responsive polymer segment, the drug-polymer conjugate having a lower critical solution temperature. In one embodiment, the molecular weight of the temperature-responsive polymer segment is 1.0×10 4 That's all. In one embodiment, the lower critical solution temperature is within the range of 0°C to 35°C. In one embodiment, the drug is at least one selected from a nucleic acid and a peptide. In one embodiment, the drug is at least one type of nucleic acid selected from an antisense oligonucleic acid, an siRNA, an miRNA, a heteronucleic acid, a CpG oligo, a nucleic acid aptamer, and a decoy nucleic acid. According to another aspect of the invention, there is provided an aggregate of the drug-polymer conjugate, the aggregate being a micellar aggregate, the temperature responsive polymer segment being disposed on the inside and the drug being disposed on the outside. In one embodiment, the micellar aggregate has a hydrodynamic diameter of 10 nm to 300 nm. According to yet another aspect of the present invention, there is provided a pharmaceutical composition comprising the drug-polymer conjugate or the micellar aggregate. In one embodiment, the pharmaceutical composition is an inhalant. According to yet another aspect of the present invention, there is provided a method for pulmonary delivery of the pharmaceutical composition, comprising intranasally or intratracheally administering the pharmaceutical composition to an individual in need of treatment. According to yet another aspect of the present invention, there is provided a method for producing the micellar aggregate, comprising: dissolving the drug-polymer conjugate in an aqueous medium at a temperature equal to or lower than the lower critical solution temperature to obtain a drug-polymer conjugate solution; and heating the drug-polymer conjugate solution to a temperature above the lower critical solution temperature to aggregate the drug-polymer conjugate. Effect of the Invention

[0008] In the present invention, a temperature-responsive drug-polymer conjugate can be used to form aggregates of the conjugate in an aqueous medium in a temperature-dependent manner. The aggregates can be absorbed through the lungs by nasal or intratracheal administration and can be suitably retained in lung tissues, thereby enabling efficient delivery of drugs to the lungs. In addition, in conventional drug delivery systems using cationic substances such as cationic lipids and cationic polymers, there is concern about the possibility of cytotoxicity due to interactions with cell membranes and mitochondrial membranes and nonspecific adsorption to proteins, but the drug-polymer conjugate of the present invention can form micellar aggregates without using cationic materials. [Brief description of the drawings]

[0009] [Figure 1A] FIG. 1 is a schematic diagram illustrating an overview of one embodiment of the present invention. [Figure 1B] FIG. 1 is a schematic diagram illustrating a variation of a drug-polymer conjugate. [Diagram 2] A gel photograph of agarose gel electrophoresis of POX(30k)-ASO prepared with various molar ratios of POX to ASO (POX / ASO). The conjugation rates at POX / ASO = 0, 1, 2, 3, 5, and 10 were 0%, 27.4%, 66.8%, 85.2%, 93.5%, and 98.8%, respectively. [Diagram 3](a) SEC charts of naked ASO (DBCO-ASO) and POX-ASO (POX(30k)-ASO) before purification detected at a wavelength of 280 nm. (b) SEC charts of POX(30k)-ASO (POX / ASO=10) before and after purification detected at a wavelength of 215 nm. [Figure 4] Graph showing relative scattered light intensity determined by static light scattering measurements performed at varying temperatures at a 10 μM ASO concentration. Results are expressed as mean ± standard deviation (n=3). [Diagram 5] FIG. 13 is a size distribution histogram of ASO balls determined by DLS measurements at 37° C. and 10 μM ASO concentration. [Figure 6] (a) TEM images of POX(30k)-ASO balls prepared at 37°C and 1 μM ASO concentration. (b) TEM images of POX(30k)-ASO balls prepared at 4°C and 1 μM ASO concentration. In the figures, the scale bar represents 100 nm. [Figure 7] Graph showing concentration-dependent changes in hydrodynamic diameter of POX(30k)-ASO as determined by FCS analysis. Results are expressed as mean ± standard deviation (sampling time: 10 s and number of repetitions: 20). [Figure 8] Figure 1 shows the expression levels of TUG1 lncRNA 48 hours after transfection with unconjugated asTUG1 or asTUG1 balls in A549-Luc cells as determined by qRT-PCR assay. Results are expressed as mean ± standard deviation (n=4; ***p<0.001 and ****p<0.0001). [Figure 9] Graph showing expression levels of TUG1 lncRNA 48 hours after transfection with unconjugated asTUG1 or asTUG1 balls in Panc1 cells as determined by qRT-PCR assay. Results are expressed as mean ± standard deviation (n=4; *p<0.05). [Figure 10]Figure 1 shows the cellular uptake efficiency, as determined by fluorescence intensity, for A549-Luc cells 6 hours after transfection with unconjugated ASO-AF6 or ASO-AF6 balls. Results are expressed as mean ± standard deviation (n=4; **p<0.01 and ****p<0.0001). [Figure 11] Graph showing cell viability 48 hours after transfection with asCTRL balls for A549-Luc cells. Results are expressed as mean ± standard deviation (n=4). [Figure 12] Ex vivo IVIS images of excised organs and tissues. [Figure 13] Graph showing fluorescence intensity of homogenized organs (liver, spleen, kidney, heart and lung) and tumors 24 hours after administration measured by microplate reader. Results are expressed as mean ± standard deviation (n=4; **p<0.01 and ****p<0.0001). [Figure 14] Figure 1 shows the expression levels of TUG1 lncRNA in tumors 72 hours after treatment, as determined by qRT-PCR assay. Results are expressed as mean ± standard deviation (n=4; **p<0.01). [Figure 15] 13 is a size distribution histogram of ASO balls prepared from POX(30k)-ASO and ASO balls prepared after addition of POX(30k) to POX(30k)-ASO, as determined by DLS measurements at 37° C. and 5 μM ASO concentration. [Figure 16] Graph showing fluorescence intensity of homogenized organs (liver, spleen, kidney, heart and lung) 24 hours after intratracheal administration measured by microplate reader. Results are expressed as mean ± standard deviation (n=3; *p<0.05). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] Hereinafter, preferred embodiments of the present invention will be described, but the present invention is not limited to these embodiments. In addition, each embodiment can be appropriately combined.

[0011] FIG. 1A is a schematic diagram for explaining an outline of one embodiment of the present invention. The temperature-responsive drug-polymer conjugate (drug-polymer conjugate) 10 illustrated in FIG. 1A includes a temperature-responsive polymer segment 12 and a drug 14 bound to one end of the temperature-responsive polymer segment 12, and has a lower critical solution temperature (hereinafter referred to as "LCST"). Specifically, the temperature-responsive drug-polymer conjugate 10 exhibits a reversible phase transition in which it is hydrated and soluble in water under a temperature condition equal to or lower than the LCST, while being dehydrated and insoluble (hardly soluble) in water under a temperature condition exceeding the LCST. Thus, in an aqueous medium, the drug-polymer conjugate 10 is in a hydrated and dissolved state at a temperature equal to or lower than the LCST, but is dehydrated and aggregated by intermolecular and / or intramolecular hydrophobic interactions at a temperature exceeding the LCST, and can form micellar aggregates 20 in which the temperature-responsive polymer segment 12 portion is arranged on the inside and the drug 14 portion is arranged on the outside. The micellar aggregates 20 can be efficiently absorbed through the lungs, and migration into the blood after pulmonary absorption is suppressed compared to when the drug 14 is administered alone, allowing the drug to be well retained in the lung tissue, thereby enabling efficient delivery of the drug to the lungs.

[0012] A. Drug-Polymer Conjugates A drug-polymer conjugate according to an embodiment of the present invention is a temperature-responsive drug-polymer conjugate comprising a temperature-responsive polymer segment and a drug bound to an end of the temperature-responsive polymer segment, and having a lower critical solution temperature (LCST).

[0013] The drug-polymer conjugate 10 shown in Fig. 1A includes a temperature-responsive polymer segment 12 and a drug 14 bound to one end of the temperature-responsive polymer segment 12. The drug-polymer conjugate 10 of this embodiment can be represented by the formula AB (wherein A represents the temperature-responsive polymer segment and B represents the drug). As described above, the drug-polymer conjugate 10 of this embodiment can form micellar aggregates 20 in which the temperature-responsive polymer segment 12 faces inward and the drug 14 faces outward in an aqueous medium at a temperature above the LCST.

[0014] The drug-polymer conjugates according to the embodiments of the present invention are not limited to the configuration shown in FIG. 1A, so long as they have an LCST and can form micellar aggregates in an aqueous medium at a temperature above the LCST, with the temperature-responsive polymer segment portion arranged on the inside and the drug portion on the outside.

[0015] For example, a modified example of a drug-polymer conjugate according to an embodiment of the present invention is shown in FIG. 1B. The drug-polymer conjugate 10' shown in FIG. 1B includes a temperature-responsive polymer segment 12, a first drug 14a attached to one end of the temperature-responsive polymer segment, and a second drug 14b attached to the other end. The drug-polymer conjugate 10' of this embodiment can be represented by the formula: B1-A-B2 (wherein A represents the temperature-responsive polymer segment, B1 represents the first drug, and B2 represents the second drug). The first drug and the second drug may be the same or different as long as the effect of the present invention is obtained.

[0016] Moreover, the drug-polymer conjugate 10'' shown in FIG. 1B includes a drug 14, a first temperature-responsive polymer segment 12a bonded to one end of the drug 14, and a second temperature-responsive polymer segment 12b bonded to the other end. The drug-polymer conjugate 10'' of this embodiment can be represented by the formula: A1-B-A2 (wherein A1 represents the first temperature-responsive polymer segment, A2 represents the second temperature-responsive polymer segment, and B represents the drug). The first temperature-responsive polymer segment and the second temperature-responsive polymer segment may have the same configuration or different configurations as long as the effects of the present invention are obtained.

[0017] According to the drug-polymer conjugate of the embodiment of the present invention, micellar aggregates in which the polymer segment portion is arranged on the inside and the drug portion is arranged on the outside can be formed by self-assembly in an aqueous medium at a temperature above the LCST. Thus, by dissolving the drug-polymer conjugate in an aqueous medium at a temperature below the LCST to prepare a drug-polymer conjugate solution and storing it as necessary, and by heating the drug-polymer conjugate solution to a temperature above the LCST when in use, micellar aggregates can be easily prepared in a completely aqueous system without using organic solvents such as alcohols, esters, and ketones.

[0018] In one embodiment, the drug-polymer conjugate has an LCST within a range of, for example, 0°C to 40°C, preferably 0°C to 35°C, more preferably 0°C to 30°C (e.g., 0°C to 25°C, 0°C to 20°C, 0°C to 15°C). According to this embodiment, a micellar aggregate can be prepared at a temperature exceeding the LCST, and the obtained micellar aggregate can be administered to an individual. The LCST can generally be determined by measuring the turbidity or scattered light intensity of a sample solution prepared at a concentration sufficient for aggregate formation (e.g., the critical association concentration or higher). That is, when determining the LCST of a drug-polymer conjugate, the turbidity or scattered light intensity can be measured while increasing the temperature of a drug-polymer conjugate solution prepared at a low temperature, and the temperature at which the turbidity or scattered light intensity begins to increase rapidly can be determined as the LCST.

[0019] In one embodiment, the drug-polymer conjugate has an LCST within the range of the body temperature of the individual to be administered to -5°C to the body temperature of the individual to be administered to. According to this embodiment, a solution of the drug-polymer conjugate can be administered to an individual to form micellar aggregates in the individual's body.

[0020] In one embodiment, the drug-polymer conjugate is hydrated and soluble in water at temperatures below 4° C. or below 10° C., while it is dehydrated in water at temperatures above 20° C., above 25° C., or above 30° C., and can aggregate into micelles at concentrations above the critical micelle concentration (CMC) at that water temperature.

[0021] Since the LCST of a drug-polymer conjugate can correspond to the LCST of a temperature-responsive polymer constituting the temperature-responsive polymer segment, a drug-polymer conjugate having a desired LCST can be obtained by adjusting the LCST of the temperature-responsive polymer.

[0022] A-1. Temperature-responsive polymer segment As the temperature-responsive polymer constituting the temperature-responsive polymer segment, any appropriate temperature-responsive polymer can be used as long as it can impart a desired LCST to the drug-polymer conjugate. In one embodiment, the temperature-responsive polymer has an LCST within a range of, for example, 0°C to 40°C, preferably 0°C to 35°C, more preferably 0°C to 30°C (e.g., 0°C to 25°C, 0°C to 20°C, 0°C to 15°C). By using a temperature-responsive polymer having an LCST within such a range, a drug-polymer conjugate having an LCST within the above desired range can be suitably obtained.

[0023] Specific examples of temperature-responsive polymers include: (a) an oxazoline repeating unit represented by the following formula (I): 1 is a methyl group, an ethyl group, an n-propyl group, an isopropyl group or an n-butyl group, preferably an n-propyl group, an isopropyl group or an n-butyl group), (b) an N-alkylacrylamide repeating unit represented by the following formula (II): 2 is a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group or a t-butyl group, preferably an n-propyl group, an isopropyl group, an n-butyl group or a t-butyl group), (c) an N-vinyl alkylamide repeating unit represented by the following formula (III): 3 is a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group or a t-butyl group, preferably an n-propyl group or an isopropyl group, and (d) a vinyl alkyl ether repeating unit represented by the following formula (IV): 4 is a methyl group, an ethyl group, an n-propyl group or an isopropyl group, preferably a methyl group or an ethyl group), Examples of the temperature-responsive polymer include a temperature-responsive polymer containing at least one repeating unit selected from the following. The temperature-responsive polymer may contain only one repeating unit represented by the following formulas (I) to (IV), or may contain two or more repeating units. Furthermore, the temperature-responsive polymer may contain repeating units other than those represented by the formulas (I) to (IV) as long as the effects of the present invention are achieved. [ka]

[0024] Poly(oxazoline)-based temperature-responsive polymers containing oxazoline-based repeating units are preferred because the degree of polymerization is easily controlled and a polymer with high monodispersity is easily obtained.Specific examples of poly(oxazoline)-based temperature-responsive polymers include poly(2-n-propyl-2-oxazoline), poly(2-isopropyl-2-oxazoline) and poly(2-n-butyl-2-oxazoline).

[0025] The LCST of a thermoresponsive polymer is determined by the R 1 ~R 4The longer the carbon chain, the lower the temperature tends to be. In addition, the LCST of a temperature-responsive polymer tends to shift to a lower temperature as the degree of polymerization increases, assuming that the types and ratios of repeating units contained in the polymer are the same. Thus, by adjusting the types, ratios, and degree of polymerization of the repeating units, a temperature-responsive polymer with a desired LCST can be obtained.

[0026] The molecular weight (in other words, mass (Da)) of the temperature-responsive polymer is preferably 1.0×10 4 More preferably, 2.0×10 4 More preferably, 3.0×10 4 The upper limit of the molecular weight of the temperature-responsive polymer is not particularly limited, but is, for example, 2.0 × 10 5 , or for example 1.0×10 5 If the molecular weight of the temperature-responsive polymer is within this range, sufficient hydrophobic interaction is obtained when the polymer is insolubilized, which is advantageous for the formation of micellar aggregates. In addition, if the molecular weight is within this range, it is easy to obtain a temperature-responsive polymer having an LCST within the desired range (as a result, a drug-polymer conjugate having an LCST within the desired range).

[0027] If necessary, a hydrophobic group may be introduced into the end of the temperature-responsive polymer segment to which the drug is not bound. Examples of such a hydrophobic group include an alkyl group or alkoxy group having 1 to 8 carbon atoms, an aryl group, an aralkyl group, an aryloxy group, or an aralkyloxy group having 6 to 12 carbon atoms, etc.

[0028] A-2. Drugs As the drug, a drug that exhibits higher hydrophilicity than the temperature-responsive polymer segment dehydrated in an aqueous medium is preferably used. By using such a drug, in an aqueous medium at a temperature exceeding the LCST, a micellar aggregate in which the temperature-responsive polymer segment is arranged on the inside to form a hydrophobic core and the drug is arranged on the outside can be easily obtained. In addition, when the drug is neutral or anionic, the surface of the micellar aggregate is neutrally or negatively charged, thereby suppressing secondary aggregation and preventing undesired interactions with biological membranes, proteins, etc. when the drug is positively charged.

[0029] The molecular weight (in other words, mass (Da)) of the drug is preferably 1.0×10 3 More preferably, 2.0×10 3 More preferably, 3.0×10 3 The upper limit of the molecular weight (in other words, mass (Da)) of the drug is not particularly limited, but is, for example, 1.0 × 10 5 , or for example 5.0×10 4 By using a hydrophilic polymer as a drug, micellar aggregates whose surfaces are coated with the hydrophilic polymer can be obtained, which is expected to reduce inflammation and provide good absorption into the lungs.

[0030] In one embodiment, the drug is a nucleic acid. Nucleic acid refers to a poly or oligonucleotide that has a nucleotide consisting of a purine or pyrimidine base, pentose, and phosphoric acid as a basic unit, and can include oligo or poly double-stranded RNA, oligo or poly double-stranded DNA, oligo or poly single-stranded DNA, and oligo or poly single-stranded RNA. It also includes oligo or poly double-stranded nucleic acid and oligo or poly single-stranded nucleic acid in which RNA and DNA are mixed in the same chain. The nucleotide contained in the nucleic acid may be natural or chemically modified non-natural, and may also be one to which molecules such as amino group, thiol group, and fluorescent compound are added.

[0031] The base length of the nucleic acid may be, for example, 5 to 150, preferably 10 to 100, and more preferably 12 to 50.

[0032] In consideration of their functions or actions, examples of the above-mentioned nucleic acids include antisense oligonucleic acids, siRNAs, miRNAs, heteroduplex nucleic acids, CpG oligodeoxynucleotides, nucleic acid aptamers, and decoy nucleic acids.

[0033] In one embodiment, the drug is a peptide. There is no limitation on the peptide as long as it has the physiological activity of a drug, and it can be appropriately selected according to the purpose. The peptide may contain only natural amino acids, or may contain non-natural amino acids.

[0034] The molecular weight (in other words, mass (Da)) of the above peptide is, for example, 1.0×10 3 ~1.0×10 4 , preferably 1.0 x 10 3 ~5.0×10 3 It could be.

[0035] A-3. Manufacturing method The drug-polymer conjugate is typically obtained by binding a drug to the end of a temperature-responsive polymer. For example, the drug-polymer conjugate represented by the formula: AB can be obtained by a method including: synthesizing a temperature-responsive polymer by polymerization reaction; introducing a first functional group to one end of the temperature-responsive polymer to obtain a one-end functionalized temperature-responsive polymer; preparing a drug having a second functional group capable of reacting with the first functional group; and reacting the first functional group with the second functional group to bind the one-end functionalized temperature-responsive polymer to the drug.

[0036] The combination of the first functional group and the second functional group may be a bond formed by the reaction of these functional groups that can be cleaved in vivo, or may be a bond that is difficult to cleave. Specific examples of the combination include an azide group and an alkyne, a thiol group and a (meth)acryloyl group, a thiol group and a maleimide group, a thiol group and a thiol group, a thiol group and a carboxyl group, a (meth)acryloyl group and a hydroxyl group, a (meth)acryloyl group and an amino group, a carboxyl group and an amino group, a carboxyl group and a hydroxyl group, an amino group and a hydroxyl group, and the like (it goes without saying that, in these combinations, either the former or the latter may be the first functional group). The second functional group may be one that is inherent in the drug, or may be one that is artificially introduced.

[0037] B. Micellar aggregates A micellar aggregate according to an embodiment of the present invention comprises a drug-polymer conjugate as described in Section A. In the micellar aggregate, the temperature responsive polymer segment is disposed on the inside and the drug is disposed on the outside.

[0038] The micellar aggregate may further contain a temperature-responsive polymer in addition to the drug-polymer conjugate described in section A. By further containing a temperature-responsive polymer, the volume of the inner part (core part) during the formation of the aggregate increases, and the particle size of the obtained micellar aggregate can be increased. In this case, from the viewpoint of ease of adjusting the particle size, it is preferable to use a temperature-responsive polymer having the same structure as the temperature-responsive polymer (segment) constituting the drug-polymer conjugate.

[0039] The particle size of the micellar aggregates (hydrodynamic diameter, D H ) can be appropriately set depending on the purpose. From the viewpoint of suppressing the transfer from the lungs to the systemic circulation after pulmonary absorption, the particle diameter (D H) is preferably 10 nm to 300 nm, more preferably 20 nm to 250 nm, even more preferably 30 nm to 200 nm, and even more preferably 40 nm to 150 nm. Aggregates having such particle sizes are favorably taken up by cells in the lungs while the subsequent transfer to the systemic circulation is inhibited, allowing efficient and localized delivery of a drug to the lungs.

[0040] The polydispersity index (PDI) of the micellar aggregates is, for example, 0.6 or less, preferably 0.4 or less, more preferably 0.2 or less, and even more preferably 0.15 or less.

[0041] The zeta potential of the micellar aggregate is typically 5 mV or less, preferably 3 mV or less, and more preferably 0 mV or less. If the zeta potential is within this range, it is possible to obtain micellar aggregates with excellent stability and to prevent undesired interactions with biological membranes, proteins, etc.

[0042] The micellar aggregates are formed by self-assembly, for example, by dissolving the drug-polymer conjugate described in Section A (and an optional temperature-responsive polymer) in an aqueous medium at a temperature below the LCST, for example at a temperature at least 10° C. lower than the LCST, and heating the resulting drug-polymer conjugate solution to a temperature above the LCST, preferably at least 10° C. higher than the LCST. The aqueous medium may be buffered as necessary, and for example, a HEPES buffer, PBS, Tris buffer, etc. may be used.

[0043] The concentration of the drug-polymer conjugate in the drug-polymer conjugate solution is not limited as long as micellar aggregates are formed, and may be, in general, a concentration equal to or higher than the critical micelle concentration at the water temperature at which the aggregates are formed. The drug-polymer conjugate concentration may be, for example, 10 nM or higher, preferably 20 nM or higher, more preferably 40 nM or higher.

[0044] C. Pharmaceutical Compositions The pharmaceutical composition according to the present embodiment includes the drug-polymer conjugate described in Section A or the micellar aggregate described in Section B. The pharmaceutical composition is preferably intended for treating or preventing lung diseases such as cancer, pleural tumor, pneumonia, pulmonary tuberculosis, pleurisy, bronchial asthma, cystic pulmonary fibrosis, and chronic obstructive pulmonary disease, as well as infectious diseases caused by microorganisms (bacteria, viruses, etc.) that cause disease in the upper and lower respiratory tracts, and complications such as respiratory insufficiency syndromes that accompany such diseases. The pharmaceutical composition according to the present embodiment is preferably delivered (absorbed through the lungs) to the upper respiratory tract (nasal cavity, pharynx, larynx) and the lower respiratory tract (trachea, bronchi, and lungs) via nasal or intratracheal administration. The cancers to be treated or prevented include not only lung cancers that originate in the lungs, but also cancers that have metastasized to the lungs from other organs.

[0045] The pharmaceutical composition is prepared into any suitable dosage form depending on the administration method. From the viewpoint of nasal administration or intratracheal administration, it is preferably an inhalant, and specific examples thereof include an inhalation liquid, an inhalation aerosol, and an inhalation powder.

[0046] The pharmaceutical composition may further contain a drug other than the drug in the drug-polymer conjugate depending on the purpose. In addition, any suitable additive may be used depending on the desired dosage form. The additive may be any pharma- ceutically acceptable one, and examples of the additive include excipients, diluents, solubilizing agents, suspending agents, isotonicity agents, pH adjusters, buffers, stabilizers, etc.

[0047] The dose of the pharmaceutical composition (specifically, the dose in terms of drug) and administration intervals can be appropriately set depending on the type and stage of the pulmonary disease, the condition of the individual to be treated, and the like.

[0048] D. Delivery method According to another aspect of the present invention, there is provided a method for delivering a pharmaceutical composition (more specifically, a drug-polymer conjugate described in Section A or a micellar aggregate described in Section B) to the lungs, comprising administering the pharmaceutical composition described in Section C intranasally or intratracheally to an individual in need of treatment. Specifically, the pharmaceutical composition can be delivered to the lungs of an individual in need of treatment by administering the pharmaceutical composition intranasally or intratracheally in a routine manner using any suitable administration device such as a nebulizer, an endotracheal tube, a microspray, etc.

[0049] The individual in need of such treatment is typically a human or non-human mammal. EXAMPLES

[0050] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples.

[0051] [Reagents, cells, experimental animals, etc.] (1) As an antisense oligonucleotide (ASO), an ASO having a phosphorothioate backbone was used (purchased from Gene Design). The sequence of the ASO is as follows (capital letters represent bridged nucleic acid (LNA) (C is LNA methylcytosine) and lower case letters represent DNA): ASO targeting taurine upregulated gene 1 (TUG1) long non-coding RNA (lncRNA): 5´-TGAAtttcaatcatttgaGAT-3´ (SEQ ID NO: 1) ASO (asCTRL) targeting GL3 luciferase and used as a control: 5'-TCGAagtactcagcgtaaGTT-3' (SEQ ID NO: 2) In addition, the 5' end of asCTRL is Alexa Fluor (R) The 647 dye was added to the ASO-AF6. For conjugation, dibenzocyclooctyne (DBCO) was added to the 3' end of asTUG1, asCTRL, or ASO-AF6. (2) The luciferase-expressing human lung cancer cell line A549-Luc was purchased from Caliper Lifesciences Corp. (Hopkinton, MA, USA) and cultured in RPMI-1640 supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin. (3) Human pancreatic cancer cell line Panc1 was purchased from the American Type Culture Collection (Manassas, VA, USA) and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin. (4) BALB / c nude mice (female, 6 weeks old) were purchased from Charles River Japan (Kanagawa, Japan), and all animal experiments were performed in accordance with the guidelines for the care and use of laboratory animals at the University of Tokyo.

[0052] [Synthesis of azide-terminated poly(2-n-propyl-2-oxazoline)] Azide-terminated poly(2-n-propyl-2-oxazoline) was synthesized according to the reaction scheme shown below. [ka]

[0053] Specifically, the following applies: First, poly(2-n-propyl-2-oxazoline) (POX) with four different molecular weights, i.e., molecular weights of approximately 5k, 10k, 20k, or 30k, respectively, were synthesized by living cationic ring-opening polymerization of 2-n-propyl-2-oxazoline. For the synthesis of 5k or 10k POX, methyl p-toluenesulfonate (61.6 mg, 0.332 mmol) as initiator was dissolved in 5 mL or 10 mL of CH3CN, respectively, followed by the addition of 2-n-propyl-2-oxazoline (1.83 g, 16.2 mmol or 3.66 g, 32.4 mmol). For the synthesis of 20k or 30k POX, methyl p-toluenesulfonate (61.6 mg, 0.332 mmol) was dissolved in 20 mL or 30 mL of a 1:1 mixture of CHCN and chlorobenzene (volume ratio), followed by the addition of 2-n-propyl-2-oxazoline (7.32 g, 64.8 mmol or 11.0 g, 97.2 mmol). The resulting mixture was stirred at 42° C. under an argon atmosphere for 4, 7, 12, or 16 days to prepare POX having a molecular weight of about 5 k, 10 k, 20 k, or 30 k, respectively. NaN3 (432 mg, 6.64 mmol) was added to the mixture and stirred at 70 °C for 3 h to terminate the reaction. The mixture was then dialyzed against methanol three times and against deionized water three times, and the product was recovered as a white powder by lyophilization. The products were characterized by MALDI-TOF-MS (ultrafleXtreme; Bruker Daltonics, Bremen, Germany) using trans-2-[3-(4-tert-butylphenyl)-2-methyl-2-propenylidene]malononitrile as the matrix and potassium trifluoroacetate as the cationic species. The obtained Mw and Mw / Mn are shown in Table 1.

[0054] [Table 1]

[0055] [Preparation of N3-POX and DBCO-ASO conjugates (POX-ASO) and gel electrophoresis] Using copper-free click chemistry with the freeze-thaw method, N3-POX was reacted with DBCO-ASO to obtain the conjugate. The reaction scheme is shown below. [ka]

[0056] As a specific example of the preparation of POX-ASO, a method for preparing POX(30k)-ASO is described below. N3-POX(30k) was dissolved in cold 10 mM HEPES buffer (pH 7.3; VWR international, Radnor, PA, USA) at a concentration of 20 mg / mL, and then mixed with asTUG1 solution (1 mg / mL in 10 mM HEPES) at various molar ratios ([molar concentration of N3 in POX] to [molar concentration of DBCO in ASO]: (POX / ASO)). The mixture was frozen overnight at -20°C and thawed at 4°C for 2 hours. This resulted in the conjugate of N3-POX(30k) and DBCO-ASO (POX(30k)-ASO).

[0057] [Gel electrophoresis of POX-ASO] Agarose gels were prepared by dissolving agarose (1 wt%) in TAE buffer (pH 7.4) containing 4 μg / mL ethidium bromide. Unconjugated ASO and POX(30k)-ASO samples were loaded onto the gel and electrophoresed (100 V, 20 min) in TAE buffer. The gels after electrophoresis were visualized with a PharosFX molecular imager (Bio-Rad, Hercules, CA). The results are shown in Figure 2.

[0058] As shown in Figure 2, the amount of free ASO decreased and the amount of conjugated POX(30k)-ASO increased with increasing POX / ASO. In addition, the ASO-derived bands were quantified using ImageJ software to determine the conjugation rate of DBCO-ASO. The amount of conjugated ASO (in other words, the amount of POX-ASO) increased with increasing POX / ASO, and at POX / ASO = 10, almost all ASO was conjugated to POX(30k) (conjugation rate: 98.8%).

[0059] [Purification of POX-ASO and size-exclusion chromatography (SEC)] The POX(30k)-ASO sample prepared at POX / ASO=10 was freeze-dried and dispersed in acetone to remove excess POX, and then centrifuged to obtain POX-ASO as a precipitate. The supernatant containing unreacted POX was decanted, and the precipitate was dispersed in acetone again, and the same procedure was repeated four times. The precipitate was then dissolved in deionized water and freeze-dried. The final product was subjected to SEC using an AKTA explorer100 system (GE Healthcare Life Sciences, Pittsburgh, PA, USA) equipped with a Superdex 75 10 / 300 GL column in 10 mM HEPES buffer (pH 7.3) containing 150 mM NaCl at 4 °C. The results of detecting ASO with UV at a wavelength of 280 nm before and after conjugation are shown in Figure 3a. In addition, POX was detected with UV at a wavelength of 215 nm before and after purification. The results are shown in Figure 3b.

[0060] As shown in Figure 3a, the POX(30k)-ASO sample prepared at POX / ASO = 10 showed a unimodal peak at 280 nm that was shifted from the DBCO-ASO peak. As shown in Figure 3b, the purified POX(30k)-ASO sample showed a clear unimodal peak at 215 nm. These results indicate that the click conjugation of N3-POX(30k) with DBCO-ASO and the purification of POX(30k)-ASO proceeded as intended.

[0061] [Preparation of micellar aggregates (ASO balls) of POX-ASO] The purified POX-ASO conjugates were dissolved in 10 mM HEPES buffer containing 150 mM NaCl at 4°C and diluted to the desired concentration (10 μM ASO for in vitro studies, 40 μM ASO for in vivo studies) with the same buffer. The sample solutions were incubated at 4°C for 20 min and then further incubated at 37°C for 20 min to prepare ASO balls.

[0062] [Light scattering analysis of ASO ball] Various POX-ASO solutions, including 10 μM asTUG1, were added to a low-volume quartz cuvette (Malvern Instruments, Worcestershire, UK), and the scattered light intensity was measured by static light scattering while increasing the temperature using a Zetasizer Nano-ZS instrument (Malvern Instruments). The temperature was increased to the next set temperature at 1°C / min and equilibrated for 2 min. The scattered light intensity was continuously measured and normalized to the initial value of each sample (i.e., the scattered light intensity at 4°C). The results are shown in Figure 4. The hydrodynamic diameter (D H The molecular weight distribution (Mg) and polydispersity index (PDI) were determined by dynamic light scattering (DLS) measurements, and the zeta potential was determined by electrophoretic light scattering (ELS). The results are shown in Table 2. The DLS histogram is shown in Figure 5.

[0063] [Table 2]

[0064] As shown in FIG. 4, in all the sample solutions of POX-ASO, an increase in the relative scattered light intensity value was observed within the temperature range of about 20°C to 40°C. From this, it can be seen that all of these POX-ASOs have an LCST within the temperature range of about 20°C to 40°C, and aggregates (ASO balls) were formed due to the transition from hydrophilicity to hydrophobicity of the POX segments at the LCST (LSCT of each POX-ASO: 5k = about 30°C, 10k = about 30°C, 20k = about 22°C, 30k = about 20°C). In addition, the increase in the relative scattered light intensity value with increasing temperature was remarkable in POX-ASOs having long-chain POX segments. Furthermore, the temperature at which the relative scattered light intensity value gradually began to increase decreased as the molecular weight of the POX segment increased. These results suggest that the molecular weight of the POX segment affects the self-assembly behavior of POX-ASO, which is probably due to the fact that the hydrophobic cohesive force of each POX segment differs depending on the molecular weight.

[0065] Also, as shown in Table 2, the ASO balls formed from POX(5k)-ASO and POX(10k)-ASO, which have relatively short POX segments, showed polydispersity indices of more than 0.3, while the ASO balls formed from POX(20k)-ASO and POX(30k)-ASO showed low polydispersity indices of less than 0.2, as shown by the unimodal peak in Figure 5, indicating that uniform aggregates were formed. In particular, the ASO balls formed from POX(30k)-ASO showed a significantly low polydispersity index of 0.08. In addition, the ASO balls showed a negative zeta potential, indicating that micellar aggregates were formed with a core formed by a hydrophobic POX segment and a negatively charged ASO shell. Note that nanoparticles larger than 100 nm can be subject to phagocytic clearance by alveolar macrophages, so the following experiments were performed using ASO balls of about 50 nm size formed from POX(30k)-ASO.

[0066] [Transmission electron microscope (TEM) observation] The ASO balls prepared from POX(30k)-ASO were observed by TEM as follows. A drop of POX(30k)-ASO sample with 10 μM asTUG1 concentration dissolved in deionized water at 37 °C or 4 °C was placed on a copper grid mesh with carbon-coated collodion and stained with 2 wt% uranyl acetate in 50% methanol. TEM images (Figures 6a and 6b) were obtained using a JEM-1400 (JEOL Ltd., Tokyo, Japan) at 120 kV.

[0067] As shown in Figure 6a, spherical structures of approximately 50 nm in size were clearly observed in the POX(30k)-ASO sample incubated at 37°C. In contrast, no structures were discernible in the POX(30k)-ASO sample incubated at 4°C (Figure 6b). These observations are consistent with those obtained from light scattering analysis.

[0068] [Fluorescence Correlation Spectroscopy (FCS) Analysis] The critical micelle concentration (CMC) of the ASO balls and the number of POX-ASO associations per ASO ball were determined by FCS analysis. FCS analysis was performed using a Zeiss LSM 880 (Carl Zeiss, Oberkochen, Germany) equipped with a ConfoCor3 module and a C-Apochromat 40× water immersion objective. Regarding the CMC of the ASO balls, the ASO ball samples were prepared by dissolving POX(30k)-ASO-AF6 at 40 μM ASO concentration in 10 mM HEPES buffer containing 150 mM NaCl and leaving it at 37 °C. The samples serially diluted to each concentration were transferred to an 8-well Lab-Tek chamber (Nalge Nunc International, Rochester, NY, USA), and fluorescence detection was performed using a 561 nm DPSS laser for excitation and a 588-691 nm bandpass filter for emission. The diffusion time was obtained with a sampling time of 10 s and 20 repetitions. The diffusion coefficient (D C ) was calculated. Strokes-Einstein formula: D H =k B T / 3πηD C (k B : Boltzmann constant, T: absolute temperature, η: dynamic viscosity) C to the hydrodynamic diameter (D H ) was calculated. The results are shown in Figure 7.

[0069] The fluorescence intensity (CPM) per unconjugated ASO molecule or per ASO ball was determined from FCS analysis of unconjugated ASO-AF6 samples or ASO ball samples prepared from a mixture of 90% POX(30k)-ASO and 10% POX(30k)-ASO-AF6, respectively. The number of POX-ASO associations per ASO ball (AN POX-ASO ) is calculated using the obtained CPM:AN POX-ASO =CPM ASOball / CPM ASOThe results were calculated from × 10. The results are shown in Table 3.

[0070] [Table 3]

[0071] As shown in FIG. 7, the ASO balls maintained a hydrodynamic diameter of 30 nm to 60 nm at ASO concentrations of about 10 nM or more to at least 40 μM (in other words, POX(30k)-ASO concentrations of about 10 nM (about 0.8 μg / mL) or more). In contrast, the size of the ASO balls was greatly reduced at ASO concentrations below 10 nM, and finally reached a size of about 5 nm at an ASO concentration of about 1 nM. The size of 5 nm may correspond to free POX-ASO. In general, pharmaceutical compositions for intratracheal administration are often concentrated from the viewpoint of increasing the volume, and secondary aggregation is easily induced by the concentration process. However, the above results show that the ASO balls do not undergo secondary aggregation even at a concentration of 40 μM and have excellent stability. In addition, in the FCS analysis for size measurement, the signal / noise ratio was higher than that of DLS under highly diluted conditions.

[0072] As shown in Table 3, the CPM obtained from the ASO ball samples was about 30 times higher than that of the unconjugated ASO-AF6 regardless of the ASO concentration, indicating that the number of POX-ASOs contained in one ASO ball was about 300. In addition, a similar analysis was performed on the ASO balls prepared from POX(20k)-ASO, and the AN at 1.25 μM and 2.5 μM ASO concentrations was 1.25 μM and 1.5 μM, respectively. POX-ASO was approximately 700, which was a higher number of associations than the ASO balls prepared from POX(30k)-ASO, a result that appears to be consistent with the relationship in the DLS histograms.

[0073] [In vitro gene knockdown assay] The gene knockdown efficiency of the ASO ball was examined using A549-Luc cells, which are cultured human lung cancer cells. Here, asTUG1 was used as the ASO. The TUG1 lncRNA targeted by asTUG1 is frequently overexpressed in various types of cancer, including lung cancer, and is known to control the proliferation and apoptosis of A549 cells. ASO ball samples were prepared at a concentration of 10 μM asTUG1 (or asCTRL) in 10 mM HEPES buffer containing 150 mM NaCl at 37°C. A549-Luc cultured cells were transfected with unconjugated ASO or ASO balls at ASO concentrations of 100 nM and 200 nM. After incubation for 48 hours, the cells were rinsed with PBS, and RNA was extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Genomic DNA was removed, cDNA was synthesized using ReverTra Ace (Toyobo, Osaka, Japan), and qRT-PCR was performed using FastStart Universal SYBR-Green Master (Roche, Basel, Switzerland) and the ABI 7500 Fast Real-time PCR System (Applied Biosystems, Foster City, CA, USA). GAPDH was applied as the endogenous housekeeping gene to determine the relative expression level of the TUG1 lncRNA. The results are presented as the mean value and standard deviation in Figure 8 (n = 4, ***p < 0.001 and ****p < 0.0001). Furthermore, the knockdown efficiency of the asTUG1 ball on Panc1 cells was determined by qRT-PCR. ASO transfection, mRNA purification, and reverse transcription into this cell line were performed as described for A549-Luc cells. The results are presented as the mean value and standard deviation in Figure 9 (n = 4, *p < 0.05).

[0074] The primer sequences used for qRT-PCR are as follows. <Primer sequences for GAPDH> forward 5´-CCA CCC ATG GCA AAT TCC-3´(SEQ ID NO: 3) reverse 5´-CAG GAG GCA TTG CTG ATG AT-3´(SEQ ID NO: 4) <Primer sequences for TUG1> forward 5´-AGG TAG AAC CTC TAT GCA TTT TGT G-3´(SEQ ID NO: 5) reverse 5´-ACT CTT GCT TCA CTA CTT CAT CCA G-3´(SEQ ID NO: 6)

[0075] As shown in Figure 8, the unconjugated TUG1-targeting ASO (asTUG1) induced a slight gene knockdown in a concentration-dependent manner. The gene knockdown ability of asTUG1 is thought to be due to the PS backbone and LNA at both ends, which enhance the resistance to nuclease and the binding affinity to the target RNA. In contrast, the ASO ball loaded with asTUG1 (asTUG1 ball) caused a significantly greater knockdown of TUG1 lncRNA compared to unconjugated asTUG1. On the other hand, no reduction in the TUG1 expression level was observed in cells treated with the ASO ball loaded with asCTRL (asCTRL ball). These results indicate that the ASO ball has sequence-specific gene knockdown ability.

[0076] Also, as shown in Figure 9, when the gene knockdown ability of the ASO ball was evaluated against human pancreatic cancer Panc1 cells overexpressing TUG1 lncRNA, the ASO ball caused a significant reduction in the expression level of TUG1 lncRNA in cultured Panc1 cells. From this, it can be seen that the gene knockdown ability of the ASO ball is not limited to a specific cell line.

[0077] Considering that the POX-ASO used in the above gene knockdown assay does not contain a specific cleavable linker between the POX segment and the ASO, the significant gene knockdown activity of the ASO ball indicates that the ASO ball and / or the dissociated POX-ASO efficiently bind to the target lncRNA. The sizes of the 21mer ASO and the hydrophobic state of POX (30) are estimated to be about 3.5 nm and about 2.5 nm, respectively. When the ASO ball dissociates through a decrease in concentration in the target cell, the about 2.5 nm-sized POX conjugated to the 3' end of the ASO is not expected to substantially inhibit the hybridization of the ASO with the target lncRNA.

[0078] [Cellular uptake evaluation] The cellular uptake of ASO-AF6 was evaluated in cultured A549-Luc cells. ASO ball samples were prepared from 10 μM ASO-AF6 in 10 mM HEPES buffer containing 150 mM NaCl at 37°C. Unconjugated ASO or ASO balls were used to transfect A549-Luc cultured cells at ASO concentrations of 100 nM and 200 nM. After 6 h of incubation, cells were rinsed twice with PBS and fresh PBS was added. The cells were then read using a microplate reader (Tecan Spark). (R) The fluorescence intensity of ASO-AF6 was measured using a fluorometer (Mannedorf Switzerland) and the relative fluorescence intensity was calculated from the obtained fluorescence values ​​as a percentage of the untreated control wells. The results are presented in Figure 10 as the mean and standard deviation (n=4, **p<0.01 and ****p<0.0001).

[0079] As shown in Figure 10, the ASO balls showed significantly higher cellular uptake efficiency than the non-conjugated ASOs, which is consistent with the higher gene knockdown activity of the ASO balls than the non-conjugated ASOs.

[0080] [Cell viability assay] ASO ball samples were prepared from 10 μM asCTRL in 10 mM HEPES buffer containing 150 mM NaCl at 37°C. A549-Luc cultured cells were transfected with unconjugated ASO or ASO balls at ASO concentrations of 100 nM, 200 nM, 400 nM, 800 nM, and 1600 nM. After 48 h of culture, the medium was replaced and cell viability was evaluated using a Cell Counting Kit-8 (Dojindo, Kumamoto, Japan). Absorbance at 450 nm was measured using a Tecan Spark Fluorescence Spectroscopy (DSS) CT scanner. (R) The relative absorbance was calculated from the absorbance values ​​obtained as a percentage of the untreated control wells. The results are presented in Figure 11 as the mean and standard deviation (n=4).

[0081] As shown in Figure 11, ASO balls showed little cytotoxicity up to an ASO concentration of 1.6 μM.

[0082] [Biodistribution of ASO balls in orthotopic xenograft tumor models] To investigate ASO delivery by ASO balls via intratracheal administration, we investigated the biodistribution in an orthotopic lung cancer model mouse. 1. Preparation of Orthotopic Xenograft Tumor Models BALB / c nude mice (female, 6 weeks old) were anesthetized with isoflurane and tumor implantation was performed as previously reported with some modifications. Specifically, a 5 mm incision was made in the dorsal skin covering the left lung of each mouse, and 3 × 10 TCID cells suspended in 40 μL PBS / Matrigel (1:1, v / v) were implanted using a 30 G needle (326668; BD, Franklin Lakes, NJ, USA). 6 A549-Luc cells were inoculated directly into the lung parenchyma at a depth of 3 mm. The wound was closed with surgical clips, and the mice were placed on a heating pad until they recovered from anesthesia. Lung cancer implantation and cancer growth were monitored by an In Vivo Imaging System (IVIS; PerkinElmer, Waltham, MA, USA), and bioluminescence images were obtained 10 min after intraperitoneal injection of D-luciferin. Tumor bioluminescence signal intensity was 10 per tumor.7 ~10 8 When the dose reached 100 photons / s, intratracheal administration was performed.

[0083] 2. Intratracheal administration Under isoflurane anesthesia, the trachea of ​​a mouse bearing an A549-Luc tumor was surgically exposed and a small incision was made in the trachea. (R) The samples were injected into the trachea using an Aerosolizer (MSA-250-M; Penn-Century, Inc., Wyndmoor, PA, USA). The incision was sutured closed, and the mouse was placed on a heating pad until it recovered from anesthesia. The ASO concentration in the sample solution was adjusted to 40 μM (which is sufficiently higher than the CMC of the ASO ball) to prevent the ASO ball from dissociating into POX-ASO monolayers during the administration process. The sample solution or the MicroSprayer was heated using a heat plate. (R) The temperature of the Aerosolizer was maintained at 37°C until just before administration, and the sample solution was administered quickly within 3 minutes. Since it has been confirmed that the ASO ball is stable at 25°C for at least 15 minutes, the above administration method can maintain the micellar structure of the ASO ball during the administration process.

[0084] 3. Biodistribution Assessment ASO ball samples were prepared from 40 μM ASO-AF6 in 10 mM HEPES buffer containing 150 mM NaCl at 37°C. Intratracheal administration of unconjugated ASO-AF6 and ASO balls into orthotopic xenograft mice (50 μL, approximately 17 μg ASO / mouse, n=4) was performed as described above. 24 hours after administration, the mice were sacrificed and individual organs, including liver, spleen, kidney, heart and lung, were excised. Tumors were isolated from the lungs of each mouse. The fluorescent signal of ASO-AF6 in the tissues was observed by IVIS (Figure 12). Each tissue was then weighed and homogenized, and the tissues were analyzed by Tecan Spark. (R) The fluorescence intensity was detected using the Fluorescence Imaging Kit. The results are presented in Figure 13 as the mean and standard deviation (n=4, **p<0.01 and ****p<0.0001).

[0085] As shown in FIG. 13, both the unconjugated ASO and the ASO balls showed significantly higher fluorescence intensity in the lung and tumor, but the fluorescence intensity of the ASO balls (44±7% and 26±6% dose g in the lung and tumor, respectively) was significantly higher than that of the nonconjugated ASO. -1 The fluorescence emission of unconjugated ASO (22±6% and 8±2% dose g in lung and tumor, respectively) was -1 This was significantly higher than that of the control tissue.

[0086] In addition, unconjugated ASO accumulated in the liver, spleen, and kidneys (4.3±0.7%, 1.2±0.3%, and 1.0±0.2% dose g in the liver, spleen, and kidneys, respectively). -1 In contrast, accumulation in these organs was barely detected in the ASO ball (<0.3% dose g -1 These results indicate that a significant amount of unconjugated ASO escaped from the lung into the systemic circulation and subsequently accumulated in other organs. In contrast, the large size of the ASO balls (50 nm) may have reduced clearance into the systemic circulation, resulting in significantly increased ASO accumulation in the lung and lung tumors.

[0087] [In vivo gene knockdown assay] The in vivo knockdown of ASO ball TUG1 lncRNA in orthotopic lung tumors was measured by qRT-PCR assay. ASO ball samples were prepared from 40 μM asTUG1 or asCTRL in 10 mM HEPES buffer containing 150 mM NaCl at 37°C. Orthotopic xenograft mice were intrabronchially administered with unconjugated asTUG1 and ASO balls (50 μL, approximately 15 μg ASO / mouse, n=4) as described above. At 72 hours after administration, the mice were sacrificed and the lungs were excised. Tumors were isolated from the lungs of each mouse and homogenized. RNA was extracted using RNeasy Mini kit, and the relative expression level of TUG1 lncRNA to GAPDH mRNA was quantified by qRT-PCR as described above. The results are presented as the mean and standard deviation in Figure 14 (n=4, **p<0.01). In addition, since the asTUG1 used in this experiment was designed to target human TUG1 lncRNA, the results obtained only reflect the gene knockdown effect in human-derived cancer cells, and do not indicate the gene knockdown effect in host mouse cells.

[0088] As shown in Figure 14, intratracheally administered asTUG1 balls (15 μg ASO / mouse) significantly reduced the expression level of TUG1 lncRNA in tumors by about 55% at 72 hours after administration, while the asCTRL ball-administered group did not show any reduction in the expression level of TUG1 lncRNA. These results indicate that intratracheally administered ASO balls exert sequence-specific gene knockdown ability in lung tumors.

[0089] In contrast, unconjugated asTUG1 did not induce significant gene knockdown in tumors. This difference in gene knockdown potential is not specific but may be due to more efficient cellular uptake and enhanced intracellular processes of the ASO ball compared to unconjugated ASO.

[0090] In particular, while ASO balls showed 55% gene knockdown at a dose of 15μg ASO / mouse, previously reported doses of 40μg ASO / mouse or 100μg ASO / mouse were required to achieve 50% or 65% gene knockdown using naked ASO, respectively (Plos One, 2017,12,e0187286). Therefore, by forming ASO balls and administering them intratracheally, it is expected that the ASO dose for gene knockdown in the lung or lung tumors can be reduced.

[0091] [Adjusting the size of ASO balls by adding POX] The POX(30k)-ASO conjugate was dissolved in 10 mM HEPES buffer containing 150 mM NaCl at 4°C and diluted to 10 μM ASO with the same buffer. The resulting POX(30k)-ASO solution was mixed with the same volume of POX(30k) solution prepared to 10 μM with the same buffer and left to stand at 4°C for 20 minutes. Then, it was further left to stand at 37°C for 20 minutes to prepare ASO balls.

[0092] The ASO ball solution prepared in the same manner except that it was mixed with 10 mM HEPES buffer containing 150 mM NaCl instead of the ASO ball solution and POX (30k) solution (as a result, POX (30k) was not added) was added to a low-volume quartz cuvette (Malvern Instruments, Worcestershire, UK) and DLS analysis was performed at 37 ° C. using a Zetasizer Nano-ZS instrument (Malvern Instruments). The obtained DLS histogram is shown in Figure 15.

[0093] As shown in FIG. 15, the addition of POX(30k) increased the size of the ASO balls while maintaining a single peak. The D HThe PDI was 109 nm / 0.11 and 50 nm / 0.06, respectively. These results confirm that the size of the ASO ball can be adjusted by adding POX without ASO to POX-ASO.

[0094] [Biodistribution of ASO balls of different sizes after tracheal administration] ASO balls were prepared from 20 μM POX(30k)-ASO samples (10 μM of which was POX(30k)-ASO-AF6) or samples containing an additional 20 μM POX(30k) in 10 mM HEPES buffer containing 150 mM NaCl at 37°C. ASO balls were administered intratracheally to BALB / c mice (50 μL, approximately 8 μg ASO / mouse, n=3) as described above. Twenty-four hours after administration, mice were sacrificed and individual organs, including liver, spleen, kidney, heart, and lungs, were excised. Each tissue was weighed and homogenized, and then analyzed using a Tecan Spark centrifuge. (R) The fluorescence intensity was detected using the Fluorescence Imaging Kit. The results are presented in Figure 16 as the mean and standard deviation (n=3, *p<0.05).

[0095] As shown in Figure 16, both types of ASO balls with different sizes had low accumulation in other organs (<0.2% dose g -1 The fluorescence intensity in the lungs was significantly higher than that in the tissue. The accumulation of ASO balls in the lungs was 79±23% and 38±10% dose g -1 Larger ASO balls showed significantly higher lung accumulation, possibly because migration into the bloodstream was more effectively inhibited with increasing ASO ball size. [Industrial Applicability]

[0096] The drug-polymer conjugate and its micellar aggregate of the present invention can be suitably used in the field of DDS.

Claims

1. An aggregate comprising a temperature-responsive drug-polymer conjugate, the aggregate comprising a temperature-responsive polymer segment and a drug bound to an end of the temperature-responsive polymer segment, The temperature responsive polymer segment is (a) an oxazoline-based repeating unit represented by the following formula (I): (in formula (I), R 1 is a methyl group, an ethyl group, an n-propyl group, an isopropyl group, or an n-butyl group); (b) N-alkylacrylamide repeating units represented by the following formula (II): (in formula (II), R 2 is a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, or a t-butyl group); (c) an N-vinyl alkylamide repeating unit represented by the following formula (III) (in formula (III), R 3 is a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group or a t-butyl group); and (d) a vinyl alkyl ether repeating unit represented by the following formula (IV): (in formula (IV), R 4 is a methyl group, an ethyl group, an n-propyl group, or an isopropyl group); At least one repeating unit selected from 【Chemistry 1】 the drug-polymer conjugate has a lower critical solution temperature; the drug is a nucleic acid, A hydrodynamic diameter of 40 nm to 300 nm; A micellar aggregate in which the temperature responsive polymer segment is disposed on the inside and the drug is disposed on the outside.

2. The micellar aggregate described in claim 1, wherein the temperature-responsive polymer segment contains an oxazoline-based repeating unit represented by formula (I) and / or an N-alkylacrylamide-based repeating unit represented by formula (II).

3. The micellar aggregate according to claim 1, wherein the temperature-responsive polymer segment has a molecular weight of 1.0×10 4 or more.

4. A micellar aggregate described in any one of claims 1 to 3, wherein the lower critical solution temperature is within the range of 0°C to 35°C.

5. A micellar aggregate described in any of claims 1 to 4, wherein the drug is at least one type of nucleic acid selected from antisense oligonucleic acid, siRNA, miRNA, heteronucleic acid, CpG oligo, nucleic acid aptamer and decoy nucleic acid.

6. A pharmaceutical composition comprising a micellar aggregate according to any one of claims 1 to 5.

7. The pharmaceutical composition according to claim 6, which is an inhalant.

8. The pharmaceutical composition of claim 6 or 7, for nasal or intratracheal administration.

9. Dissolving the drug-polymer conjugate in an aqueous medium at a temperature equal to or lower than the lower critical solution temperature to obtain a drug-polymer conjugate solution; and 6. A method for producing a micellar aggregate according to any one of claims 1 to 5, comprising heating the drug-polymer conjugate solution to a temperature above the lower critical solution temperature to aggregate the drug-polymer conjugate.

Citation Information

Patent Citations

  • Temperature-responsive micelle and use therefor

    JP2019038787A